Product Description
engineered Lactococcus lactis secreting human IL-10
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ActoGeniX N.V.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Colitis, Ulcerative
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2008-000967-40 | P2 |
Active, not recruiting |
Colitis, Ulcerative |
2009-10-14 |
|
AG011-MDUC-201 | P2 |
Completed |
Colitis, Ulcerative |
2009-09-01 |